HER2-Positive Breast Cancer Market Set to Reach $14.41 Billion by 2029 with 7% Yearly Growth

What Is the Estimated Market Size and Growth Rate for the HER2-Positive Breast Cancer Market?
Over the recent years, the HER2-positive breast cancer market has seen robust growth. The market size is set to increase from $10.21 billion in 2024 to $10.96 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.34%. Factors that have influenced this increase in the historic period include the surge in early detection and diagnosis, heightened awareness of HER2-positive subtypes, higher funding in research and development, increased utilization of precision medicine, and a greater emphasis on bolstering patient outcomes.

The market size of HER2-positive breast cancer is anticipated to experience robust growth in the upcoming years, estimated to escalate to $14.41 billion in 2029, with a compound annual growth rate (CAGR) of 7.08%. This projected growth in the future years is due to the increasing demand for liquid biopsy for non-invasive checks, growth in the use of combination therapies, rising prominence on immunotherapies and new drug forms, expanding the application of liquid biopsy methods for non-intrusive monitoring, and the growing number of specialized cancer treatment institutions. Key trends during the forecasting period includes advancements in targeted treatments, innovative formulations, breakthroughs in immunotherapy strategies, the advancement of new HER2-focused therapies, and improvements in biomarkers for improved patient classification.

What Are the Forces Behind the Rapid Growth of the HER2-Positive Breast Cancer Market?
The increasing acceptance of immunotherapy is predicted to drive the expansion of the HER2-positive breast cancer sector in the future. Immunotherapy involves a therapeutic approach that boosts or alters the immune mechanism's innate capability to combat diseases such as cancer, infections, and autoimmune disorders. The adoption of immunotherapy is credited to its power to boost the immune mechanism's aptitude to detect and eradicate cancer cells, yielding superior efficacy and lesser side effects compared to traditional treatments. Immunotherapy assists in fighting HER2-positive breast cancer by intensifying the body's immune response to identify and assault HER2-overexpressing cancer cells, ameliorating treatment outcomes and diminishing the chance of disease reoccurrence. For example, by July 2023 as per the American Association for Cancer Research, a US-based entity, the FDA had given approval to 11 immune checkpoint inhibitors (ICIs) in 2023, with a minimum of one ICI endorsed for the treatment of 20 distinct cancer kinds and for any solid tumor demonstrating specific molecular attributes. Hence, the growing acceptance of immunotherapy is propelling the expansion of the HER2-positive breast cancer market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp

Who Are the Dominant Companies Influencing HER2-Positive Breast Cancer Market Trends?
Major companies operating in the HER2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

How Is the HER2-Positive Breast Cancer Market Evolving?
Leading businesses in the HER2-positive breast cancer market are concentrating on the creation of innovative therapies like HER2-directed antibody-drug conjugates (ADCs) to improve and refine patient treatment procedures. HER2-directed ADCs are specialized cancer therapies that connect a HER2-specific antibody with a cytotoxic drug, effectively directing the medication straight to HER2- positive cancer cells. In January 2024, AstraZeneca India Pharma Ltd, an Indian biopharmaceutical firm, introduced Trastuzumab deruxtecan. Developed in partnership with Daiichi Sankyo, this groundbreaking therapy is a HER2-directed ADC that delivers a cytotoxic drug directly to HER2-positive cancer cells, providing a more focused and potent treatment for patients.

What Are the Different Segmentations in the HER2-Positive Breast Cancer Market?
The HER2-positive breast cancer market covered in this report is segmented -

1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User

Subsegments:
1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors
2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens
3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines
5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

Which Region Is at the Forefront of the HER2-Positive Breast Cancer Market?
North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The HER2-Positive Breast Cancer Global Market Report?

- Market Size Analysis: Analyze the her2-positive breast cancer Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the her2-positive breast cancer Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall her2-positive breast cancer market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the her2-positive breast cancer market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20832

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.